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Cisplatin (CDDP) is one of the most active drugs to treat nasopharyngeal carcinoma (NPC) patients. To further understand
the mechanisms of CDDP-resistance in NPC, two CDDP-resistant sublines (CNE2-CDDP and CNE2-CDDP-5Fu) derived from
parentalNPCcelllineCNE2wereestablished.ItwasfoundthatattheIC50level,theresistanceofCNE2-CDDPandCNE2-CDDP-
5Fu against CDDP was 2.63-fold and 5.35-fold stronger than that of parental CNE2, respectively. Of the four ABC transporters
(ABCB1, ABCC1, ABCC2 and ABCG2) related to MDR, only ABCC2 was found to be elevated both in CDDP-resistant sublines,
with ABCC2 located in nucleus of CNE2-CDDP-5Fu but not in CNE2-CDDP and parental CNE2. Further research showed that
compared to untreated CNE2, the intracellular levels of CDDP were decreased by 2.03-fold in CNE2-CDDP and 2.78-fold in
CNE2-CDDP-5Fu. After treatment with PSC833, a modulator of MDR associated transporters including ABCC2, the intracellular
level of CDDP was increased in CDDP-resistant sublines, and the resistance to CDDP was partially reversed from 2.63-fold to
1.62-fold in CNE2-CDDP and from 5.35-fold to 4.62-fold in CNE2-CDDP-5Fu. These data indicate that ABCC2 may play an
important role in NPC resistant to CDDP.
1.Introduction
Nasopharyngeal carcinoma (NPC) is a major malignant dis-
ease of the head and neck region and is endemic to Southeast
Asia and Mediterranean basin, especially in Southern China
[1, 2]. Since NPC originates from a hidden anatomical
site and is more closely associated with advanced clinical
stage, the results of conventional radiotherapy technique
are unsatisfactory although it is a radiosensitive tumor.
Therefore, chemotherapy treatment is a necessary ancillary
method for these NPC patients [3, 4].
cis-Diamminedichloroplatinum (CDDP), also known as
cisplatin, which is the most active and most frequently
employed drugs, is often used to treat distant metastasis
or advanced locoregional recurrence of NPC patients, and
the chemotherapeutic regimen of CDDP plus 5-ﬂuorouracil
(5-Fu) is the main drug combination used in clinical trials
[5, 6]. However, inherent and acquired resistance to the
drug limits its applications in NPC chemotherapy. The
mechanisms of resistance to CDDP are complicated. Of
all these mechanisms, the one that is most commonly
encountered in the laboratory is the increased eﬄux of
abroad class of hydrophobic cytotoxic drugs that is medi-
ated by one of a family of energy-dependent transporters,
known as adenosine triphosphate binding cassette (ABC)
transporters [7]. The ABC transporters have the capa-
bility to use energy to drive the transporters of various
molecules across the cellular membrane and are con-
ﬁrmed to be associated with anticancer drug transporter
[8].
Several members of the ABC transporter family can
induce multidrug resistance (MDR). So far, tissue culture
studies have consistently shown that the major mechanism
of MDR in most cultured cancer cells involves ABCB1(also2 Journal of Oncology
known as P-glycoprotein, P-gp, or MDR1), ABCC1 (also
known as multidrug resistance associated-protein 1, MRP1),
or ABCG2 [7]. ABCC2, also known as MRP2 or cMOAT,
had been identiﬁed to confer cellular resistance of tumor
cells to various anticancer drugs including CDDP [9]. Our
previousstudyhadconﬁrmedthatlentivirus-mediatedRNAi
silencing targeting ABCC2 might reverse the ABCC2-related
drug resistance of NPC cell line CNE2 against CDDP
[10].
To further illustrate the mechanism of CDDP-resistance,
CDDP-resistant subline was established from parental NPC
cell line CNE2. Given that the chemotherapeutic regimen
of CDDP plus 5-Fu was widely used in clinic, CDDP-5Fu-
resistant cell line derived from parental CNE2 was also
established. PSC 833, a second-generation powerful MDR
modulator [11], was utilized to reverse the CDDP-resistance
in these cells. The modulation of ABCC2 expression was
detected, and high performance liquid chromatograph
(HPLC) was used to detect the intracellular accumulation of
CDDP in these cells with or without PSC 833.
2. Methods
2.1. Cell Lines and Cell Culture. The human NPC cell line
CNE2 was grown in RPMI-1640 medium(Hyclone, Logan,
UT) supplemented with 10% fetal calf serum (ExCell,
Cranford, NJ) and 1% L-glutamine [12]. The CDDP-
resistantandCDDP-5Fu-resistantsublinesweregeneratedby
continuously culturing the drug-sensitive parental cell line
CNE2 in medium containing large dose of CDDP (1μg/mL)
and CDDP (1μg/mL) plus 5-Fu (1μg/mL) for over 1 year.
To avoid an inﬂuence of CDDP or 5-Fu, all resistant sublines
were cultured in drug–free medium for over 1 month before
subsequent analysis. All Cells were cultured at 37
◦Ci na
humidiﬁed incubator with 5% CO2.
2.2. Cytotoxicity Assays by MTT. The cytotoxicity of CDDP
to cells was determined using the MTT assay. Cells were
seeded into 96-well plates at a density of 5 × 103 cells
per well. To investigate the eﬀect of PSC 833, cells were
incubated with or without 2μg/mL PSC 833 (Sandoz, Basel,
Switzerland). Various gradient concentrations of CDDP (Qi
Lu Pharmaceutical Factory, Jinan, China) ranging from 0.5
to 32μg/mL were added to each well 24 hours after seeding.
Wells containing no drugs or PSC 833 were used to control
cell viability, and wells containing no cells were used as a
blank control. After 48 hours of incubation under normal
culture condition, MTT was added at a ﬁnal concentration
of 5mg/mL. Four h later, DMSO (Sigma, Louis, MO, USA.)
was added to each well to dissolve the crystal with shaking
horizontally for ten minutes [13]. The optical density (OD)
value of 570nm wavelength was measured by microplate
reader (Bio Rad, Hercules, CA). The IC50 value, deﬁned as
the drug concentration required to reduce cell survival to
50% determined by the relative absorbance of MTT, was
assessed by probit regression analysis in SPSS11.5 statistical
software.Theresistanceindex(RI)wascalculatedbydividing
the IC50 of the CDDP-resistant sublines by that of parental
cell line CNE2 [14]. All experiments were performed in
triplicate.
2.3. Analysis of Cell Viability by MTT Assay. MTT assay was
conducted to determine the cell proliferation. Cells were
seededintoseven96-wellplatesatadensityof1×103 cellsper
well. Wells containing no cells were used as a blank control.
A MTT assay was done daily from the second to the eighth
day of incubation. The OD value of each well was measured
as described above. Independent experiments were done in
triplicate. Growth curves were drawn according to the OD
values [15].
2.4. Analysis of ABCC2 mRNA Levels by Quantitative
Real-Time PCR. Total RNA from all cells were extracted
using Trizol reagent (Invitrogen, Carlsbad, CA) and reverse
transcribed to cDNA using PrimeScript kit (Takara bio,
Otsu, Japan) following the manufacturer’s instructions.
Real-time PCR was performed with MX3000P instru-
ment (Stratagene, Cedar Creek, TX) using a commer-
cially available master mix SYBR Premix Ex Taq kit
(Takara bio, Otsu, Japan) containing Taq DNA poly-
merase and SYBR-Green I ﬂuorescence dye. The primer
sequences for target genes were as follows: ABCB1 for-
ward, 5 -TAATGCGACAGGAGATAGG-3 , ABCB1 reverse,
5 -AAGAACAGGACTGATGGC-3 ; ABCC1 forward, 5 -
GAGGAAGGGAGTTCAGTCTT-3 , ABCC1 reverse, 5 -
ACAAGACGAGCTGAATGAGT-3 ; and ABCC2 forward,
5 -CTCACTTCAGCGAGACCG-3 , ABCC2 reverse, 5 -
CCAGCCAGTTCAGGGTTT-3 ; ABCG2 forward, 5 -ACC-
TGAAGGCATTTACTGAA-3 ,A B C G 2r e v e r s e ,5  -TCT-
TTCCTTGCAGCTAAGAC-3 ; The primer sequences for
referencegeneACTB(alsoknownasβ-actin)wereasfollows:
ACTB forward: 5 -CACCCAGCACAATGAAGAT-3 ;A C T B
reverse: 5 -CAAATAAAGCCATGCCAAT-3 . Cycling condi-
tions were used as described previously [16]: 95
◦Cf o r1 0
minutes to activate DNA polymerase, followed by 45 cycles
of 95
◦C for 15 seconds, 55
◦C for 20 seconds, and 72
◦Cf o r1 0
seconds. Speciﬁcity of ampliﬁcation products was conﬁrmed
by melting curve analysis. Each sample was assayed in
triplicate in independent reactions. The cycle threshold (Ct),
which represents a positive PCR result, is deﬁned as the
cycle number at which a sample’s ﬂuorescence crossed the
thresholdautomaticallydeterminedbytheMX3000Psystem.
The relative changes in gene expression were calculated
with the 2−ΔΔCt method, where ΔCt = Ct(target gene)—
Ct(ACTB), and ΔΔCt = ΔCt (sample)—ΔCt (calibrator) [17,
18]. Here sample refers to CDDP-resistant and CDDP-5Fu-
resistant CNE2 sublines, while calibrator refers to parental
cell line CNE2.
2.5. Analysis of ABCC2 Protein Levels by Immunocyto-
chemistry. Cells were seeded on slides, incubated under
normal culture conditions for overnight, ﬁxed in acetone
for 30 minutes at 4◦C, washed with PBS, and air-dried.
After treated by endogenous biotin block system (MaiXin
Biotechnology, Fuzhou, China), the slides were incubated in























Figure 1: The growth curves of CDDP-resistant sublines and
parental cell line CNE2. The cell viability was performed by MTT
method for 7 continuously days.
and then in 10% normal rabbit serum for 10 minutes to
block nonspeciﬁc antibody binding sites. When blocking
was complete, the slides were then incubated with speciﬁc
antibody against human ABCC2 ((Boster, Wuhan, China)
in a 1:100 dilution in PBS at 4◦C overnight. Subsequently,
the slides were detected with the biotin-streptavidin- peroxi-
dase system (Ultra Sensitive-SP kit; MaiXin Biotechnology,
Fuzhou, China) at room temperature, using diaminoben-
zidine (MaiXin Biotechnology, Fuzhou, China) as color
presentation (1–3min). Counterstaining for nuclei was per-
formed with hematoxylin. Negative controls were performed
by substituting the speciﬁc antibody with PBS [19, 20].
2.6. Drug Accumulation Assays by High Performance Liquid
Chromatograph. One day after cells were seeded in 25cm2
ﬂasks, CDDP (10μg/mL) was added to the ﬂasks with or
without PSC 833 (10μg/mL). Two h later, cells were har-
vested with 0.025% trypsin and 0.02% EDTA. Subsequently,
they were counted by a haemocytometer, with total 106 cells
to be used. After washing by RPMI-1640 for three times,
cell pellets were collected and resuspended in 0.3ml distilled
water, followed by freeze/thaw for 5 times to breakdown the
cells. The mixtures were then centrifuged at 12,000r.p.m
for 30 minutes. Finally, 10μL of the supernatant containing
CDDP content were analyzed by HPLC (series 1200, Agilent,
Santa. Clara, CA, USA) [10, 21]. CDDP standard solutions
ranging from 5 to 80μg/mL were used for preparation of
calibration curve. Each sample was measured at least three
times.
2.7. Statistic Analysis. All experiments were repeated at least
three times. The data of quantitative RT-PCR, IC50, and
intracellular accumulation of CDDP were expressed as mean
± SD value. Statistical analysis for these data was carried out
by one-way ANOVA in statistical package SPSS 11.5. P < .05
was considered signiﬁcant.
Table 1: Modulation of resistance against CDDP with or without
PSC 833.
Cell lines IC50 (RI)
CDDP CDDP plus PSC 833
CNE2 0.90 ± 0.14 (1) 0.89 ± 0.25 (1)
CNE2-CDDP 2.37 ± 0.37 (2.63)∗ 1.44 ± 0.10 (1.62)∗∗
CNE2-CDDP-5Fu 4.82 ± 0.84 (5.35)∗ 4.11 ± 0.25 (4.62)∗∗
RI: resistance index (x-fold) compared to parental CNE2
∗(∗∗): P < .05 versus CNE2.
3. Results
3.1. Resistance to CDDP is Enhanced in Drug-Resistant
Sublines and Can Be Partially Reversed by PSC 833. The
CDDP-resistant sublines, CNE2-CDDP, and CNE2-CDDP-
5Fu, were generated after more than 1 year of culture.
Cellular growth was determined by a continuous 7-day MTT
assay, and growth curve was made according to the OD value
alterationsofMTTassay.Nosigniﬁcantdiﬀerencewasfound
between the cellular growth of these cells (Figure 1). Table 1
summarized all the IC50 obtained testing CDDP. At the IC50
level, the resistance of CNE2-CDDP and CNE2-CDDP-5Fu
against CDDP was 2.63-fold and 5.35-fold stronger than
that of CNE2, respectively. In the parental cell line CNE2,
PSC 833 was inactive, whereas in CNE2-CDDP and CNE2-
CDDP-5Fu, the resistance against CDDP was reversed by
PSC 833 from 2.63-fold to 1.62-fold and 5.35-fold to 4.62-
fold, respectively. These data indicated that two CDDP-
resistant sublines are established successfully, with more
acquired CDDP-resistance in CNE2-CDDP-5Fu, and the
CDDP-resistance can be partially reversed by PSC 833.
3.2. Of the ABC Transporters Related to MDR, ABCC2
mRNA is Highly Expressed in the Drug-Resistant Sublines.
Several members of the ABC transporter family including
ABCB1, ABCC1, ABCC2, and ABCG2 can induce MDR
[7, 9]. Modulation of these ABC transporters was detected
by relative real-time PCR. Of the four ABC transporters,
ABCC2 was found to be upregulated both in CNE2-CDDP
and CNE2-CDDP-5Fu (Table 2). Compared to untreated
CNE2, the expression level of ABCC2 mRNA in CNE2-
CDDP and CNE2-CDDP-5Fu was 2.46-fold and 4.29-fold
increased, respectively. These data showed that in CDDP-
resistant sublines, ABCC2 mRNA was overexpressed, with
more expression level in CNE2-CDDP-5Fu.
3.3. The Expression of ABCC2 Protein Is Enhanced in the
Drug-Resistant Sublines. Since ABCC2 was found to be
overexpressed both in CNE-CDDP and CNE2-CDDP-5Fu,
and previous studies have shown that ABCC2 can be
localized in the nuclear membrane of CDDP-resistant cells
[22], immunocytochemistry staining method was used to
detect the ABCC2 protein expression. As shown in Figure 2,
ABCC2 protein was found to be localized in cytoplasm. The
expression level of ABCC2 protein in CDDP-resistant sub-
lines was stronger than that in parental CNE2. Interestingly,4 Journal of Oncology
Table 2: Relative quantiﬁcation of four ABC transporters.
ABC transporters CNE2 CNE2-CDDP CNE2-CDDP-5Fu
ΔCt ΔCt Fold change (2−ΔΔCt) ΔCt Fold change (2−ΔΔCt)
ABCB1 22.6 ± 0.3 22.8 ± 0.5 0.87 22.2 ± 0.5 1.32
ABCC1 12.8 ± 0.2 13.3 ± 0.2 0.71 14.1 ± 0.1 0.41
ABCC2 10.9 ± 0.1 9.6 ± 0.1∗ 2.46 8.8 ± 0.1∗ 4.29
ABCG2 16.2 ± 0.2 16.0 ± 0.6 1.15 14.8 ± 0.5∗ 2.64
∗P < .05 versus CNE2.
(a) (b)
(c) (d)
Figure 2: Immunocytochemical staining of ABCC2 expression in three cells (×200; SP method, DAB staining, and counterstaining with
hematoxylin). (a) Blank control; (b) Parental cell line CNE2; (c) CDDP-resistant CNE2-CDDP cells; and (d) CDDP-5Fu-resistant CNE2-
CDDP-5Fu cells. Black arrow: ABCC2 protein localized in cytoplasm; red arrow: ABCC2 protein localized in nucleus.
ABCC2 protein was also found to be localized in nucleus of
CNE2-CDDP-5Fu cells.
3.4.IntracellularAccumulationofCDDPintheDrug-Resistant
Sublines Are Decreased and Can Be Increased by PSC 833.
ABC transporters have the capability to use energy to drive
the transporters of various molecules across the cellular
membrane [8]. As a measure of the functional activity
of ABCC2 which was overexpressed in CDDP-resistant
sublines, the detection of intracellular accumulation of
CDDP was carried out by HPLC. As shown in Figure 3(a),
a symmetrical peak for typical chromatograms of CDDP
was found, and retention time for CDDP was 1.55 minutes.
Figure 3(b)showedatypicallinearrelationship(R2 =0.9965)
between peak height value and gradient concentration of
CDDP. The equation obtained from this calibration curve is
y = 1.59x+17.92, where y stands for the peak height value of
CDDP and x stands for the concentration of CDDP. Thereby
the intracellular concentration of CDDP for each sample
wasanalyzed(showninFigure 3(c)).Comparedtountreated
CNE2,theintracellularlevelofCDDPwasdecreasedby2.03-
fold in CNE2-CDDP and 2.78-fold in CNE2-CDDP-5Fu. In
contrast, after treatment with PSC 833, the intracellular level
ofCDDPwasdecreasedfrom2.03-foldto1.33-foldinCNE2-
CDDP and from 2.78-fold to 1.35-fold in CNE2-CDDP-5Fu,
which indicate that the intracellular accumulation of CDDP
in CNE2-CDDP and CNE2-CDDP-5Fu was increased after
PSC 833 treatment. No signiﬁcant modulation was found in
CNE2. These data suggest that the capacity to drive CDDP
out of cells in CDDP-resistant sublines is enhanced and can
be partially reversed by PSC 833.
4. Discussion
Chemotherapy with CDDP is widely used to treat NPC
patients. Primary and secondary resistance to CDDP are
major limitations to their use in cancer chemotherapy.
Improvedunderstandingofthebiologicmechanismsleading
to CDDP resistance will provide molecular targets for
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Figure 3: Intracellular accumulation of CDDP. (a) A typical chromatogram for total analysis of CDDP using HPLC determination. (b)
Calibration curve for gradient concentration of CDDP within the range of 5–80μg/ml. A typical linear relationship (R2 = 0.9965) was found
between peak height and concentration of cisplatin. (c) The cellular accumulation of CDDP in parental CNE2 and resistant sublines. The
concentration of CDDP was determined according to the calibration curve of CDDP. CNE2 resistant sublines were treated with or without
PSC 833. ∗P < .05 versus CNE2.
response and therewith the basis for individually tailored
therapy.
To further understand the mechanisms of CDDP-
resistance, two CDDP-resistant sublines, CNE2-CDDP and
CNE2-CDDP-5Fu, derived from parental NPC cell line
CNE2, were established. The resistance was found to be
stable for over 1 month in drug-free medium. No diﬀerence
was found between the cellular growth of these cells. The
resistance against CDDP, compared to untreated CNE2, was
2.63-fold for CNE2-CDDP and 5.35-fold for CNE2-CDDP-
5Fu, respectively. These data suggest that the CDDP-resistant
sublines were established successfully, with more acquired
resistance against CDDP in CNE2-CDDP-5Fu than that in
CNE2-CDDP.
After the CDDP-resistant sublines were generated, the
mRNAlevelsofthefourmembersofABCtransporterfamily,
ABCB1, ABCC1, ABCC2, and ABCG2, which were found
to be associated with MDR [7], were detected by real-time
PCR. Only ABCC2 was found to be up-regulated both in
CNE2-CDDP and CNE2-CDDP-5Fu and was conﬁrmed by
immunocytochemichal staining. ABCC2 had been shown
to be a unidirectional ATP-driven export pump localized
mainly in the canalicular membrane of hepatocytes [23]. In
vitro data suggest that ABCC2 might act as an organic anion
pump [24, 25]. On the other hand, the expression of ABCC2
was found to be elevated in a number of cell lines selected
for CDDP resistance [9, 26]. In addition, our previous study
had demonstrated that the speciﬁc RNAi targeting ABCC2
led to greater cytotoxicity of CDDP to CNE2 [10].Thesedata
indicated that ABCC2 is related to CDDP-resistance. In this
study, compared to CNE2-CDDP, increased expression of
ABCC2wasobservedinCNE2-CDDP-5Fu,whichwasfound
to be shown more acquired CDDP-resistance than CNE2-
CDDP.OurresultsimplythatABCC2mayplayanimportant
role in the CDDP-resistance of NPC cell line CNE2.
Previous studies conﬁrmed that ABCC2 was localized
in the nuclear membrane of CDDP-resistant cells, and
nuclear membranous localization of ABCC2 correlated with
resistance against CDDP in ovarian carcinoma cells [22, 27].
Furthermore, it had been reported that after treatment with
RNAi targeting ABCC2, decreased nuclear membranous
ABCC2 protein expression in the CDDP-resistant cancer cell
lines was observed [28]. In this study, ABCC2 protein was
also found to be localized in the nucleus of the more CDDP-
resistant subline CNE2-CDDP-5Fu, but not in CNE2-CDDP
and parental CNE2. The cellular target of CDDP has long
been believed to be DNA, for it has been shown to bind DNA
and cause DNA duplex to bend and unwind. Thus, ABCC26 Journal of Oncology
may protect the nucleus from formation of platinum-
DNA adducts by driving CDDP out of the cytoplasm and
nucleus.
To further conﬁrm that CDDP can be driven out of
cells by ABCC2, HPLC, which is an eﬀective method to
detect the intracellular accumulation of CDDP, was applied.
HPLCwasarapid,economic,andvalidatedwaytodetermine
the accumulation of CDDP in plasma, cancer cell, and
tumorsamples[29].Ourresultsshowedthattheintracellular
accumulation of CDDP in CNE2-CDDP and CNE2-CDDP-
5Fu was decreased compared to CNE2. Since in the four
ABC transporters (ABCB1, ABCC1, ABCC2, and ABCG2)
related to drug resistance, only ABCC2 was found to be up-
regulated both in CNE2-CDDP and CNE2-CDDP-5Fu, and
previous study had demonstrated that after treatment with
RNAi targeting ABCC2, the cellular accumulation of CDDP
in CNE2 was increased [28], it was inferred that probably
ABCC2 has the capacity to drive CDDP out of the cytoplasm
of CDDP-resistant sublines. Furthermore, compared to
CNE2-CDDP, less intracellular accumulation of CDDP was
found in CNE2-CDDP-5Fu. It was noted that ABCC2 was
found to be localized in nucleus of CNE2-CDDP-5Fu. These
data indicated that may be nuclear localized ABCC2 has
the capacity to drive CDDP out of the nucleus of CNE2-
CDDP-5Fu, which results in more acquired resistance to
CDDP.
The MDR-associated transporters inspired a wide search
for compounds that would not be cytotoxic themselves
but would inhibit MDR transporters. The ﬁrst of these
drugs to be studied was PSC 833, a nonimmunosuppres-
sive cyclosporine D derivative and less toxic compared to
cyclosporine A, and also known to inhibit ABCC1 and
ABCC2 [11, 30, 31]. In our research, after treatment with
PSC 833, the intracellular accumulation of CDDP in subline
CNE2-CDDP and CNE2-CDDP-5Fu was increased, with
increased cytotoxicity of CDDP. Given that of the four ABC
transporters, only ABCC2 was found to be up-regulated
both in CNE2-CDDP and CNE2-CDDP-5Fu, and PSC 833
was a modulator of MDR-associated transporters including
ABCC2, the role of ABCC2 in driving CDDP out of
cytoplasm may be interfered by PSC 833, which further
imply that ABCC2 may play an important role in CDDP-
resistance.
In our research, ABCC2 was found to be localized
in nucleus of CNE2-CDDP-5Fu, but not in CNE2-CDDP.
Moreover, less intracellular accumulation of CDDP and
more acquired resistance against CDDP were found in
CNE2-CDDP-5Fu compared to CNE2-CDDP. These results
suggest that the combination of CDDP and 5-Fu may result
in the nuclear localization of ABCC2, thus CDDP may be
driven out of nucleus and more resistance against CDDP was
acquired. The regimen of CDDP plus 5-Fu chemotherapy is
widely used to treat NPC patients. Our results imply that
p e r h a p ss u c har e g i m e nw i l lr e s u l ti ng r e a t e rc y t o t o x i c i t y
to tumor cells, yet it will make the remaining tumor cells
more resistant to CDDP, probably mediated by ABCC2, and
ﬁnally lead to poor prognosis. The relationship between the
expression of ABCC2 in NPC patients and CDDP-resistance
in clinic should be further studied.
5. Conclusion
Taken together, derived from parental NPC cell line CNE2,
two CDDP-resistant sublines (CNE2-CDDP and CNE2-
CDDP-5Fu) were developed, hence a good cell model to
study the mechanisms of CDDP-resistance was established.
We demonstrated that the expression of ABCC2 was both
elevatedinCNE2-CDDP-5FuandCNE2-CDDP,andABCC2
protein was found to be localized in nucleus of CNE2-
CDDP-5Fu, but not in CNE2-CDDP and parental CNE2.
Furthermore, less intracellular accumulation of CDDP in
CDDP-resistant sublines compared to parental CNE2 was
found. Therewith, more acquired CDDP-resistance was
found in CDDP-resistant sublines compared to CNE2. Of
these cell lines, the most resistance against CDDP was found
in CNE2-CDDP-5Fu, with ABCC2 localized in nucleus
and the least intracellular accumulation of CDDP. The
intracellular accumulation of CDDP and CDDP-resistance
can be partially reversed by PSC 833, a modulator of MDR-
associatedtransportersincludingABCC2.Thesedatasuggest
that ABCC2 may play an important role in NPC resistant to
CDDP, indicating that ABCC2 may be taken as one of the
targets to overcome CDDP-resistance in NPC.
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